JW Pharmaceutical announced on Monday that it has completed the registration of a U.S. patent for its hair loss treatment candidate, JW0061, which targets the GFRA1 receptor.
The newly registered patent protects the substance related to novel heterocyclic derivatives of JW0061, including its salts and isomers. It safeguards the technology used for treating and preventing various types of hair loss, such as androgenetic alopecia and alopecia areata.
The patent will remain valid until May 2039, securing JW Pharmaceutical’s exclusive rights in the U.S. market for an extended period.
JW Pharmaceutical has successfully registered the substance patent for JW0061 in nine countries, including the U.S., South Korea, Japan, China, Australia, and Brazil. Patent examinations are ongoing in Europe and Canada.
JW0061 is an innovative first-in-class candidate drug being developed as a topical treatment that acts on the GFRA1 mechanism. This compound directly binds to the GFRA1 receptor expressed in hair follicle stem cells, activating downstream signaling pathways that stimulate hair follicle formation and hair growth.
The company has presented JW0061’s preclinical research results at several international conferences, including the Society for Investigative Dermatology (SID). Studies using human skin organoids and androgenetic alopecia animal models have shown JW0061’s superiority in hair growth rate and hair follicle generation compared to existing standard treatments.
Building on these promising preclinical results, JW Pharmaceutical recently submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) for JW0061’s Phase 1 clinical trial.
A spokesperson for JW Pharmaceutical stated that the U.S. patent registration for JW0061 represents official recognition of our core technology’s competitiveness in the world’s largest pharmaceutical market. It is committed to advancing clinical development without delays and aim to establish JW0061 as a groundbreaking global treatment for hair loss.